Therapeutic target database update 2014: a resource for targeted therapeutics
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Here we describe an update of the Therapeutic Target Database (http://bidd.nus.edu.sg/group/ttd/ttd.asp) for better serving the bench-to-clinic communities and for enabling more convenient data access, processing and exchange. Extensive efforts from the research, industry, clinical, regulatory and management communities have been collectively directed at the discovery, investigation, application, monitoring and management of targeted therapeutics. Increasing efforts have been directed at the development of stratified and personalized medicines. These efforts may be facilitated by the knowledge of the efficacy targets and biomarkers of targeted therapeutics. Therefore, we added search tools for using the International Classification of Disease ICD-10-CM and ICD-9-CM codes to retrieve the target, biomarker and drug information (currently enabling the search of almost 900 targets, 1800 biomarkers and 6000 drugs related to 900 disease conditions). We added information of almost 1800 biomarkers for 300 disease conditions and 200 drug scaffolds for 700 drugs. We significantly expanded Therapeutic Target Database data contents to cover >2300 targets (388 successful and 461 clinical trial targets), 20 600 drugs (2003 approved and 3147 clinical trial drugs), 20,000 multitarget agents against almost 400 target-pairs and the activity data of 1400 agents against 300 cell lines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517 · cited 1×
“For instance, many drugs have been derived from individual scaffold groups such as macrocycles (60), and 12 FDA-approved anticancer kinase inhibitor drugs (61,62) are grouped into three scaffold groups (63).”
BackgroundMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Trends in the exploitation of novel drug targets
Rask-Andersen, M., Almén, M. S., & Schiöth, H. B. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3478 · Cited by 853
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. (2012) · Nature · doi:10.1038/nature10937 · Cited by 446 · cited 1×
“The knowledge of the efficacy targets and biomarkers is useful not only for the discovery and development of targeted therapeutics (11,12) but also for facilitating the development and practice of stratified and personalized medicines (4,13,14).”
BackgroundIn search of biomarkers for autism: scientific, social and ethical challenges
Walsh, P., Elsabbagh, M., Bolton, P., & Singh, I. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3113 · Cited by 249
Molinari, F., Felicioni, L., Buscarino, M., De Dosso, S., Buttitta, F., Malatesta, S., Movilia, A., Luoni, M., Boldorini, R., Alabiso, O., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3137 · Cited by 159
Mechanistic biomarkers for clinical decision making in rheumatic diseases
Robinson, W. H., Lindstrom, T. M., Cheung, R. K., & Sokolove, J. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.14 · Cited by 109
Cited by
Brettin, T., Davis, J. J., Disz, T., Edwards, R. A., Gerdes, S., Olsen, G. J., Olson, R., Overbeek, R., Parrello, B., Pusch, G. D., et al. (2015) · Scientific Reports · doi:10.1038/srep08365 · Cited by 2,819
The Drug Repurposing Hub: a next-generation drug library and information resource
Corsello, S. M., Bittker, J. A., Liu, Z., Gould, J., McCarren, P., Hirschman, J. E., Johnston, S. E., Vrcic, A., Wong, B., Khan, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4306 · Cited by 1,015
The BioGRID interaction database: 2017 update
Chatr-aryamontri, A., Oughtred, R., Boucher, L., Rust, J., Chang, C., Kolas, N. K., O'Donnell, L., Oster, S., Theesfeld, C., Sellam, A., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1102 · Cited by 965
Understanding multicellular function and disease with human tissue-specific networks
Greene, C. S., Krishnan, A., Wong, A. K., Ricciotti, E., Zelaya, R. A., Himmelstein, D. S., Zhang, R., Hartmann, B. M., Zaslavsky, E., Sealfon, S. C., et al. (2015) · Nature Genetics · doi:10.1038/ng.3259 · Cited by 832
DSigDB: drug signatures database for gene set analysis
Yoo, M., Shin, J., Kim, J., Ryall, K. A., Lee, K., Lee, S., Jeon, M., Kang, J., & Tan, A. C. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv313 · Cited by 750
Metadata
- Authors
- Qin, C., Zhang, C., Zhu, F., Xu, F., Chen, S. Y., Zhang, P., Li, Y. H., Yang, S. Y., Wei, Y. Q., Tao, L., & Chen, Y. Z.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-11-21
- Volume
- 42
- Issue
- D1
- Pages
- D1118-D1123
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W1975426150
- Cited by
- 121
- References
- 8
- FWCI
- 15.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic target database update 2014: a resource for targeted therapeutics. https://app.cochat.ai/papers/10.1093/nar/gkt1129
- The paper
- Qin, C., Zhang, C., Zhu, F., Xu, F., Chen, S. Y., Zhang, P., Li, Y. H., Yang, S. Y., Wei, Y. Q., Tao, L., & Chen, Y. Z. (2014). Therapeutic target database update 2014: a resource for targeted therapeutics. Nucleic Acids Research. https://doi.org/10.1093/nar/gkt1129
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.